Answers are grounded in this paper and cite their sources.
T cells in adenocarcinoma NSCLC patients. In addition, our results lead to envisage the possible therapeutic usage of IL-18 in NSCLC, even in combination with other checkpoint inhibitor approaches.
No takes yet. Share an insight, caveat, or question.
Timperi et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: